ITC gains as Q4 PAT zooms 290% YoY to Rs 19,562 cr; declares dividend of Rs 7.85/sh
ITC added 1.80% to Rs 433.75 after the company's standalone net profit spiked 289.65% to Rs 19,561.57 crore in Q4 FY25 as against Rs 5,020.20 crore posted in Q4 FY24.
Revenue from operations (excluding excise duty) was at Rs 17,248.21 crore in the March quarter FY25, up 9.26% year on year.
Profit before tax rose 2.05% year on year to Rs 6,416.85 crore in Q4 FY25.
EBITDA improved by 2.46% year-on-year to Rs 5,986 crore in Q4 FY25, from Rs 5,842 crore in Q4 FY24.
The companys FMCG Others segment reported a 5.06% year-on-year growth in revenue to Rs 13,894.24 crore in Q4 FY25, despite subdued demand conditions and a sharp rise in input costs.
The revenue from Cigarettes rose by 5.99% YoY to Rs 8,399.61 crore in the fourth quarter of FY25.
The Agri Business segment posted a 17.68% year-on-year rise in revenue to Rs 3,649.16 crore in Q4 FY25, driven by strong performance in leaf tobacco, value-added agri products, and rice exports.
The companys paperboards, paper and packaging segment remained impacted by low-priced imports from China and Indonesia, subdued domestic demand, and a sharp surge in wood prices. Segmental revenue for paperboards, paper & packaging rallied 5.53% YoY to Rs 2,187.62 crore in Q4 FY25.
The companys Hotels Business has been classified as Discontinued Operations in the financial results for the year ended 31st March 2025, in accordance with applicable Indian Accounting Standards. The business has been demerged into ITC Hotels Limited (ITCHL) w.e.f. 01 January 2025. ITCHL shares listed on stock exchanges on 29 January 2025.
The Incense Sticks (Agarbattis) category continued to witness robust growth during the year, with the companys flagship brand Mangaldeep capitalising on market opportunities and strengthening its market position.
The business delivered a robust performance during the year, with the Value-Added Agri Products (VAAP) portfolio posting strong growth, led by higher exports of spices and coffee.
Meanwhile, the Board has approved a final dividend of Rs 7.85 per share for the financial year FY25. Additionally, the re-appointment of Shyamal Mukherjee as a Director, and as an independent director for a five-year term, effective from 11th August 2026, has been recommended for approval by the members.
Separately, ITC announced the acquisition of shares in Mother Sparsh Baby Care. The acquisition comprises 594 equity shares of Rs 10 each, acquired through a secondary purchase from an existing shareholder of Mother Sparsh, and 2,201 compulsorily convertible preference shares (CCPS) of Rs 10 each, subscribed through a primary issuance. The cost of acquisition for the shares is approximately Rs 50.6 crore.
The company does not have any promoters or promoter group. Additionally, the group companies have no interest in Mother Sparsh.
Following the acquisition, the companys shareholding in Mother Sparsh has increased from 26.50% to 39.47% of its share capital on a fully diluted basis.
The acquisition aligns with the companys strategy to build a future-ready portfolio of products catering to evolving consumer needs. Mother Sparsh, a premium Ayurvedic and natural personal care start-up, specializes in baby personal care, health & hygiene, and expert baby care. The Indian baby care market is experiencing significant growth, driven by factors such as rising disposable incomes and increasing awareness about the demand for safer baby products.
ITC is a diversified conglomerate with businesses spanning fast-moving consumer goods, hotels, paperboards and packaging, agribusiness and information technology.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
12 minutes ago
- News18
Influx Healthtech IPO Allotment: A Step-By-Step Guide To Check Status Online Today, Know Latest GMP
Last Updated: According to market observers, the GMP of the Influx Healthtech IPO is 22.92%, indicating decent listing gains for investors. Influx Healthtech IPO Allotment: The initial public offering of Influx Healthtech has received a whopping 201.35 times subscription, indicating huge interest from investors. Investors are now eagerly awaiting its allotment even its latest GMP shows a strong 22.92% listing gains. The allotment of the Influx Healthtech IPO is expected to be finalised today, Monday, June 23, in the evening. Once the IPO allotment is finalised, investors will start receiving bank debit messages, most probably in the evening. They can also check their allotment status on the websites of the NSE as well as registrar Maashitla Securities Private Limited. The allotment is expected to be finalised in the evening today, Friday, June 20. The allotment status can be checked by following these steps: Step 1: Visit Maashitla Securities' portal — Step 2: Under 'Select Company', choose 'Influx Healthtech Ltd'. Importantly, if the company's name is not visible in the drop-down list, it means the allotment has not been finalised yet. According to market observers, the GMP of the Influx Healthtech IPO is 22.92%, indicating decent listing gains for investors. The GMP is based on market sentiments and keeps changing. 'Grey market premium' indicates investors' readiness to pay more than the issue price. Influx Healthtech IPO Listing Date The shares of Influx Healthtech Ltd will be listed on the NSE Emerge on June 25. The Influx Healthtech IPO was open for subscription between June 18 and June 20. It is a book-built issue worth Rs 58.57 crore, comprising a fresh issue of 50 lakh equity shares worth Rs 48 crore and an offer for sale of 11 lakh shares aggregating to Rs 10.56 crore. On the final day of bidding on Friday, the SME IPO received an overwhelming 201.35 times subscription, garnering bids for 81,71,71,200 shares as against 40,58,400 shares on offer. The retail and NII participation stood at 117.68 times and 481.10 times, respectively. Its qualified institutional buyer (QIB) category got a 137.87 times subscription. The price of the Influx Healthtech IPO was fixed at Rs 96 apiece. Influx Healthtech Ltd's revenue increased 5% and its profit after tax (PAT) rose 19% between the financial year ending with March 31, 2025, and March 31, 2024. Rarever Financial Advisors Pvt Ltd is the book-running lead manager of the Influx Healthtech IPO, while Maashitla Securities Private Limited is the registrar for the issue. The market maker for Influx Healthtech IPO is R K Stock Holding Private Limited. Influx Healthtech Ltd, founded in September 2020, is a healthcare-focused CDMO with three manufacturing units in Thane, producing tablets, capsules, powders, liquid orals, and softgels.
India.com
15 minutes ago
- India.com
Good news for Anil Ambani, another company settles Rs 2730000000 loan of…, with…
Anil Ambani was already in the news for settling down the debt of his many companies. Now once again it has settled the debt with another company. In a recent exchange filing it stated that it has fully settled a Rs 273-crore loan, including interest, owed by its wholly owned subsidiary JR Toll Road Pvt Ltd (JRTR) to Yes Bank Ltd. It stated, '' A wholly owned subsidiary of the Company (along with the Company as Corporate Guarantor), has entered into an addendum to the Settlement Agreement today with Yes Bank Limited (YBL) for the entire outstanding debt obligation of ~INR 273 crore (including interest) owed by JRTR to YBL, and has duly paid the entire settlement amount.'' Anil Ambani Company Debt Reduction Debt reduction has become a primary focus for Anil Ambani. Reliance Infrastructure: Paid off Rs 3,300 crore of debt in FY 2025, becoming debt-free. Rosa Power Supply Company: Cleared Rs 485 crore of debt, achieving debt-free status. Reliance Power: Settled a loan of Rs 3,872 crore earlier. JR Toll Road Pvt Ltd, a special purpose vehicle established by Reliance Infrastructure, is responsible for the development, operation, and maintenance of a 52-kilometer segment of National Highway 11, connecting Jaipur and Reengus in Rajasthan. The project was executed under the Design-Build-Finance-Operate-Transfer (DBFOT) model, featuring a highway expansion from four to six lanes. Operations commenced in 2013, coinciding with the start of toll collection.
Hindustan Times
16 minutes ago
- Hindustan Times
Watch with Kannada numerals and Karnataka's iconic crest goes viral: 'Decolonize your mind'
BJP MP Tejasvi Surya criticizes Karnataka's Rs 18,000 crore tunnel road project, calling it unscientific and financially unsound. He questions the project's feasibility, high toll costs, and potential public fund drain, challenging the government's transportation strategy.
